Cargando…
mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential
Metastasis is the biggest challenge in treating breast cancer, and it kills >40,000 breast cancer patients annually in the US. Aberrant expression of the RON receptor tyrosine kinase in breast tumors correlates with poor prognosis and has been shown to promote metastasis. However, the molecular m...
Autores principales: | Faham, Najme, Zhao, Ling, Welm, Alana L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226524/ https://www.ncbi.nlm.nih.gov/pubmed/30456298 http://dx.doi.org/10.1038/s41523-018-0091-5 |
Ejemplares similares
-
RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses
por: Eyob, Henok, et al.
Publicado: (2013) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016) -
Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018) -
The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
por: Cunha, Stéphanie, et al.
Publicado: (2014) -
Hyperactivity of mTORC1 or mTORC2-dependent signaling causes epilepsy downstream of somatic PTEN loss
por: Cullen, Erin R., et al.
Publicado: (2023)